Drug Profile
SIM 688
Alternative Names: SIM-688; WAY-204688Latest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule; Wyeth
- Developer Wyeth
- Class Fluorobenzenes; Nitriles; Piperidines
- Mechanism of Action Estrogen receptor agonists; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 11 Jan 2005 Phase-I clinical trials in Rheumatoid arthritis in USA (PO)